Skip to main content
. 2020 May 15;22(11):1614–1624. doi: 10.1093/neuonc/noaa121

Fig. 2.

Fig. 2

Survival analysis of patients in the study. (A) Survival of IDH wildtype diffuse glioma (grades II‒IV) patients according to the F3T3 status (median OS = 29.1 mo for F3T3-positive vs 20.5 mo for F3T3-negative; P = 0.04). (B) Survival of IDH wildtype glioblastoma (GBM) patients treated with standard radiation therapy plus concomitant and adjuvant temozolomide after surgery or biopsy, according to the F3T3 status (median OS, 31.1 mo for F3T3-positive vs. 19.9 mo for F3T3-negative, P = 0.02). (C) Survival of F3T3-positive patients according to grade (P = 0.37). (D) Survival of GBM patients according to F3T3 and IDH status (median OS, 29.1 mo for F3T3-positive/IDH wildtype GBM vs 19.9 mo for F3T3-negative/IDH wildtype GBM, P = 0.04; median OS not reached for F3T3-negative/IDH mutant, P < 0.001). Tick marks represent censored patients.